495,00 €
Prenatal screening test based on cfRNA to estimate the risk of early-onset preeclampsia.
The peace of mind of knowing that your pregnancy is cared for with rigour and knowledge.
Yes, the test is performed from a maternal blood sample and poses no risk.
The standard turnaround time for results is 3 weeks from receipt of the sample
Your doctor will assess the result and adapt the monitoring of the pregnancy.
Yes, MaiRa can be integrated into the usual monitoring of the pregnancy.
Preeclampsia is a pregnancy complication characterised by the onset of high blood pressure, organ damage and other symptoms. It can progress to severe forms such as eclampsia (seizures), with a risk to maternal and fetal life.
Preeclampsia affects approximately 1 in every 20 pregnancies globally. Although it is not very common, its impact can be significant if it is not detected in time.
Yes. In many women, preeclampsia does not present clear symptoms in its early stages, which makes early detection difficult without specific tools.
Because anticipating it makes it possible to:
Early information helps
